United Arab Emirates Influenza Treatment Market Size, Share & Trends Analysis Report By Product (Peramivir, Zanamivir, Oseltamivir Phosphate, Baloxavir Marboxil), By Distribution Channel (Retail Pharmacy, Hospital Pharmacy) and By Country (U.S., Canada) Forecasts, 2026-2034

Market Driving Factors

Increased Incidence of Respiratory Infections and Government Health Initiatives

Influenza remains a significant public health concern in the UAE, particularly during the colder months, with annual flu seasons contributing to a rise in hospital visits and medication consumption. The Emirates Disease Control Center (EDCC) reports that influenza cases increase by 15% annually, leading to greater demand for antiviral drugs. Additionally, the country’s healthcare reforms and vision for 2030 have supported the expansion of healthcare infrastructure, ensuring improved access to treatment. Public health initiatives like vaccination campaigns and increasing awareness of flu symptoms also contribute to the demand for flu treatments.

Additionally, government programs to improve public health and healthcare facilities have encouraged local and international pharmaceutical companies to invest in antiviral treatments. The UAE Ministry of Health and Prevention (MOHAP) has also introduced several policies to promote the use of antiviral agents, creating a favorable environment for the market’s growth. Healthcare institutions in the UAE are increasingly adopting innovative antiviral solutions, stimulating the market’s growth.

Market Restraining Factors

High Treatment Costs and Limited Insurance Coverage

Despite the growing demand for influenza treatments in the UAE, high treatment costs remain a significant barrier. Antiviral drugs, which often come with a high price tag, may only be affordable for some patients, particularly those without adequate insurance coverage. Furthermore, the regional insurance policies in the UAE may only sometimes cover all flu treatments, resulting in out-of-pocket expenses for patients. While the government has made strides in improving access to healthcare, disparities still exist in affordability, particularly among expatriate populations.

Another challenge is uniform healthcare coverage across the public and private sectors. Patients who do not have comprehensive health insurance or government-sponsored treatment plans may struggle to afford flu medications. This can hinder the overall accessibility of treatment and slow market growth.

Key Market Opportunity

Emerging Demand for Locally Acting Antiviral Agents and Technological Integration

One of the most promising opportunities in the UAE influenza treatment market is the increasing adoption of locally acting antiviral agents. These drugs, designed to directly target the virus without causing widespread side effects, are gaining popularity due to their efficiency and lower impact on overall health. Companies like Gilead Sciences and Roche are already making significant inroads into the region with antiviral products tailored to local healthcare needs.

Furthermore, integrating advanced technologies such as Artificial Intelligence (AI) and telemedicine presents opportunities for better flu diagnosis and treatment. AI-based diagnostic tools are helping physicians in the UAE provide quicker and more accurate flu diagnoses, resulting in more efficient treatment. The growing adoption of telemedicine is also transforming how flu treatments are delivered, with patients able to consult healthcare providers remotely for prescriptions and guidance. This integration aligns with the UAE's digital health goals and provides a significant market opportunity.

Segmentation Analysis

By Drug Type

Locally Acting Antiviral Agents dominate the drug type segment and are expected to grow at a CAGR of 4.3% over the forecast period. These drugs are gaining traction because they offer targeted treatment that minimizes adverse effects, making them a preferred option for physicians and patients. The rise in chronic conditions such as diabetes and hypertension, which increase susceptibility to influenza complications, drives demand for these treatments. Additionally, the UAE's pharmaceutical market is gradually shifting toward adopting innovative drugs tailored to local healthcare needs, creating favorable conditions for the growth of locally acting antivirals.

By End User

Hospitals and clinics continue to dominate the end-user segment of the UAE influenza treatment market, with an expected CAGR of 4.6%. The increasing availability of advanced healthcare facilities, supported by government investments, ensures that hospitals remain the primary location for influenza diagnosis and treatment. The UAE government’s initiatives to strengthen healthcare infrastructure, mainly through the Dubai Health Authority (DHA) and Abu Dhabi Health Services (SEHA), have contributed to a rise in hospital-based treatments. Additionally, the growing emphasis on specialized medical centers dealing with respiratory diseases has increased hospital visits for influenza treatment.

Request Customizationto receive a tailored report.

Speak to an Analystto discuss market opportunities.

Citywise Insights

The market is characterized by significant regional disparities in healthcare access, technological advancement, and disease burden across the UAE. While the overall market is expanding, the growth pattern is influenced by key cities and healthcare policies aimed at improving access and treatment outcomes.

• Dubai is at the forefront of the UAE influenza treatment market, with its robust healthcare infrastructure and a high concentration of private and public hospitals. The city is home to leading medical centers, such as the American Hospital Dubai, which offers advanced treatment options. Dubai’s emphasis on medical tourism has also contributed to its role as a hub for healthcare services, attracting patients from across the region. The increasing number of expatriates and tourists further boosts the demand for influenza treatment, ensuring the city’s dominance in the market.
• Abu Dhabi plays a crucial role in the country’s healthcare landscape as the capital of the UAE. The city has made significant strides in establishing cutting-edge medical facilities, such as the Cleveland Clinic Abu Dhabi, which provides state-of-the-art influenza treatment services. With government investments in healthcare infrastructure and ongoing public health campaigns, Abu Dhabi’s market is expected to grow rapidly.
• Sharjah is witnessing growth in influenza treatment demand due to increasing healthcare facilities catering to the local population and expatriates. The rise in respiratory diseases and the city’s emphasis on improving healthcare services contribute to the growth of the influenza treatment market. Partnerships between private hospitals and international pharmaceutical companies are also supporting market expansion.
• Ajman, with its emerging healthcare sector, is seeing an increase in demand for influenza treatments, mainly as the city develops its medical infrastructure. The introduction of advanced clinics and treatment centers is helping improve access to antiviral medications, driving market growth. The government’s healthcare initiatives in Ajman further support the market's upward trajectory.
• Fujairah's healthcare sector, though smaller than Dubai or Abu Dhabi, has shown strong growth in recent years. The government’s efforts to upgrade medical facilities and provide accessible healthcare have contributed to the increased adoption of influenza treatments. Regional hospitals in Fujairah are equipped with modern antiviral treatments, ensuring the growth of the influenza treatment market in the region.

List of Key and Emerging Players in United Arab Emirates Influenza Treatment Market

• Roche Holding AG
• GlaxoSmithKline plc
• AstraZeneca plc
• Sanofi S.A.
• Seqirus (a subsidiary of CSL Limited)
• Johnson & Johnson
• Pfizer Inc.
• Novartis International AG
• Daiichi Sankyo Company, Limited
• Mylan N.V.